ClinicalTrials.gg
CompletedNCT06977490Updated May 22, 2026

Human Bioequivalence Study of Amphotericin B Liposome for Injection

An interventional study of Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.) and Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences) in Invasive Fungal Infections, Neutropenic Fever and Visceral Leishmaniasis, sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-22.

Sponsored by Sichuan Huiyu Pharmaceutical Co., Ltd · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Invasive Fungal Infections with a site in China — 12 open to participants now, 12 under way, none of them phase 3. Invasive Fungal Infections · China.

Enrollment
9th of 12
42 · median 74
Started
2025
with 6 others
No phase
3 of 29
1 open now
Registered
19th of 29
by date
Lead sponsor
2 of 29
Sichuan Huiyu Pharmaceutical Co., Ltd

Among the 29 studies in Invasive Fungal Infections with a site in China, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is one of 7 that started in 2025, is one of 3 with no phase, and was the 19th registered.

Invasive Fungal Infections

136 studies on the registry are indexed under Invasive Fungal Infections; 33 are open to participants now.

Browse Invasive Fungal Infections studies →

Open to participants now

12 of the 29 studies in Invasive Fungal Infections with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Invasive Fungal Infections studies recruiting now, 12 (60%) set no upper age limit and 5 (25%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Invasive Fungal Infections with a site in China, or all of them as a file.
02

Study summary

Single-center, randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design to evaluate the human bioequivalence of two Amphotericin B Liposome for Injection formulations

Read the detailed description

To evaluate the human bioequivalence of Amphotericin B Liposome for Injection (strength: 50 mg) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. and Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences) by comparing the differences in the extent and rate of absorption between the two formulations in a healthy Chinese population under a single-center, randomized, open-label, single-dose, two-treatment, two-period, two-sequence crossover design.

03

Conditions studied

  • Invasive Fungal Infections
  • Neutropenic Fever
  • Visceral Leishmaniasis
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The enrolled participants shall meet all of the following criteria:

  1. The study participants must give before the trial, fully understand the content, process and possible adverse reactions, and voluntarily sign a written informed consent;
  2. The study participants can communicate well with the investigators and complete the trial according to protocol;
  3. Sex: female or male; age: 18-50 years (inclusive);
  4. (BMI): 19-28 kg/m2 (inclusive), with a minimum weight of 50.0 kg for males and 45.0 kg for females (BMI = Body weight / Height2 [kg/m2]).

Exclusion criteria

Exclusion Criteria:

Study participants meeting one or more of the following criteria will be excluded:

  1. Allergic constitution (such as those allergic to two or more drugs or foods [e.g., milk], or pollen), or known history of allergy to the components of the study drug or similar drugs (API: amphotericin B; : hydrogenated soy phosphatidylcholine, cholesterol, distearoylphosphatidylglycerol [sodium salt], alpha tocopherol, sucrose, disodium succinate hexahydrate, hydrochloric acid, and sodium hydroxide); (inquiry)
  2. Subjects with the following diseases of clinical significance (including but not limited to diseases related to respiratory system, circulatory system, digestive system, blood system, endocrine system, immune system, skin system, psycho-neurological system, ophthalmology and otorhinolaryngology); (inquiry)
  3. Subjects with gastrointestinal, liver and kidney diseases that affect the pharmacokinetics of drugs; (inquiry)
  4. Subjects who underwent major surgery within 6 months prior to initial administration, or who planned to undergo surgery during the study; (inquiry)
  5. abnormalities in vital signs, physical examination, and laboratory tests (blood biochemistry, hematology, urinalysis, coagulation); (as determined by the clinical investigator)
  6. Subjects with a history of , , AIDS (Acquired Immune Deficiency Syndrome), syphilis and/or abnormalities in one or more of the four tests for infectious diseases with clinical significance; (as determined by the clinical investigator)
  7. Blood loss or blood donation of greater than or equal to 400 mL within 3 months prior to initial administration (except for female menstrual period), and/or donation within 2 weeks prior to initial administration; (inquiry)
  8. Use of any prescription medicine within 14 days prior to initial administration or use of any over-the-counter medicine, Chinese herbal medicine or health product within 7 days prior to initial administration (except for topical drugs with local effects); (inquiry)
  9. Use of azoles (e.g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.), skeletal muscle relaxants, and adrenal cortical hormones, antineoplastic agents, digitonin, flucytosine or other nephrotoxic medications within 28 days prior to initial administration; (inquiry)
  10. Subjects who received vaccines or within 4 weeks prior to the administration of the study drug, or who planned to be vaccinated during the trial; (inquiry)
  11. Subjects who received medication in any clinical trial or participated in any medical device clinical trial within 3 months prior to initial administration; (inquiry + online screening)
  12. A history of drug abuse within 5 years, and/or drug use within 3 months prior to screening, and/or habitual use of any drug (including Chinese herbs) or positive urine drug screening; (inquiry + as determined by the clinical investigator)
  13. Subjects who smoked more than 5 cigarettes per day within 3 months prior to screening and/or did not agree to refrain from using any tobacco products during the trial; (inquiry)
  14. Regular drinkers within 6 months prior to screening, i.e., subjects who drank more than 14 units of alcohol per week (1 unit = 360 mL of beer with 5% alcohol or 45 mL of spirits with 40% alcohol or 150 mL of wine with 12% alcohol), or subjects who did not agree to stop drinking alcohol 48 h prior to initial administration and during the trial, or test positive for breath alcohol;
  15. Subjects who consume excessive amounts of tea, coffee and/or caffeinated beverages (more than 8 cups, 1 cup = 250 mL) per day within 6 months prior to screening, and/or do not agree that tea, coffee and/or caffeinated foods, grapefruit and/or grapefruit juice, and/or products containing opium poppy are prohibited 48 h prior to initial administration and during the trial; (inquiry)
  16. Subjects who have a birth plan (including sperm or egg donation) and/or do not agree to take effective methods (non-drug during the trial period) from signing form to 6 months after the final administration; (inquiry)
  17. Pregnant or lactating women or subjects with positive pregnancy results; (inquiry, for females only)
  18. Subjects who have used oral contraceptives within 30 days prior to initial administration; (inquiry)
  19. Use of long-acting estrogen and/or progesterone injections and/or implants within 6 months prior to initial administration; (inquiry, females only)
  20. Women of childbearing age who have unprotected sex with their partner within 14 days prior to initial administration; (inquiry, females only)
  21. Subjects who cannot tolerate venipuncture or have a history of needle and blood sickness; (inquiry)
  22. Subjects who may not be able to complete the study for other reasons or who the investigator considers should not be included.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Amphotericin B Liposome for Injection (Sichuan Huiyu Pharmaceutical Co., Ltd.)

    * Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.) * The test product

    Drug: Amphotericin B Liposome for Injection (strength: 50 mg, Sichuan Huiyu Pharmaceutical Co., Ltd.)

  • Experimental
    Amphotericin B Liposome for Injection (trade name: Ambisome®)

    * Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences) * The reference product

    Drug: Amphotericin B Liposome for Injection (trade name: Ambisome®, strength: 50 mg, MAH: Gilead Sciences)

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    90% confidence interval is within the 80.00%-125.00% equivalence margin.

    Time frame: 0 hour before safe dose and 0 hour before formal dose to 1320 hours post formal dose

  2. AUC0-t

    90% confidence interval is within the 80.00%-125.00% equivalence margin.

    Time frame: 0 hour before safe dose and 0 hour before formal dose to 1320 hours post formal dose

  3. AUC0-∞

    90% confidence interval is within the 80.00%-125.00% equivalence margin.

    Time frame: 0 hour before safe dose and 0 hour before formal dose to 1320 hours post formal dose

  4. AUC0-10h

    90% confidence interval is within the 80.00%-125.00% equivalence margin.

    Time frame: 0 hour before safe dose and 0 hour before formal dose to 1320 hours post formal dose

  5. AUC10-last

    90% confidence interval is within the 80.00%-125.00% equivalence margin.

    Time frame: 0 hour before safe dose and 0 hour before formal dose to 1320 hours post formal dose

Secondary outcomes

  1. Tmax

    90% confidence intervals will also be investigated as supportive data.

    Time frame: 0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose

  2. λz

    90% confidence intervals will also be investigated as supportive data.

    Time frame: 0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose

  3. t1/2

    90% confidence intervals will also be investigated as supportive data.

    Time frame: 0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose

  4. AUC_%Extrap

    90% confidence intervals will also be investigated as supportive data.

    Time frame: 0 h before safe dose and 0 h before formal dose to 1320 hours post formal dose

07

Study locations

1 site
  • Jinan Central Hospital, No.105, Jiefang Road,
    Jinan, Shandong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Oct 2025, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2025
First posted
May 18, 2025
StartActual
May 13, 2025
Primary completionActual
Oct 7, 2025
CompletionActual
Oct 7, 2025
Last update
May 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06977490
Collaborators
Changsha King-eagle Med Technology Co., Ltd.
Responsible party
Sponsor
First posted
May 18, 2025
Start date
May 13, 2025
Primary completion
Oct 7, 2025
Completion
Oct 7, 2025
Last update
May 22, 2026

Study contacts

Qing Wen
study director · Jinan Central Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amphotericin B

Start the discussion